WO2012078288A2 - Méthodes de détermination du risque d'évolutions défavorables dans la leucémie myéloïde aiguë - Google Patents

Méthodes de détermination du risque d'évolutions défavorables dans la leucémie myéloïde aiguë Download PDF

Info

Publication number
WO2012078288A2
WO2012078288A2 PCT/US2011/059843 US2011059843W WO2012078288A2 WO 2012078288 A2 WO2012078288 A2 WO 2012078288A2 US 2011059843 W US2011059843 W US 2011059843W WO 2012078288 A2 WO2012078288 A2 WO 2012078288A2
Authority
WO
WIPO (PCT)
Prior art keywords
dnmt3a
accordance
adverse outcome
subject diagnosed
determining risk
Prior art date
Application number
PCT/US2011/059843
Other languages
English (en)
Other versions
WO2012078288A3 (fr
Inventor
Timothy J. Ley
Richard K. Wilson.
Elaine K. Mardis
Li Ding
John K. Dipersio.
Original Assignee
Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University filed Critical Washington University
Publication of WO2012078288A2 publication Critical patent/WO2012078288A2/fr
Publication of WO2012078288A3 publication Critical patent/WO2012078288A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • DNMT3A haploinsufficiency is not deleterious to mice (Okano, M., et al., Cell 99: 247-257, 1999), and complete loss of DNMT3A in the bone marrow cells of mice does not overtly alter hematopoiesis in the short term (Tadokoro, Y., et al., J. Exp. Med. 204:715-722, 2007).
  • lymphocytes (Xu, G.L., et al., Nature 402: 187-191 , 1999; Hansen, R.S., et al.

Abstract

La présente invention a pour objet des méthodes de détermination du risque d'évolution défavorable chez un sujet chez qui on a diagnostiqué une leucémie myéloïde aiguë ou un syndrome myélodysplasique. Les méthodes comprennent les étapes consistant à prévoir un échantillon comprenant des cellules de moelle osseuse et/ou du sang périphérique prélevé sur un sujet chez qui on a diagnostiqué une leucémie myéloïde aiguë ou un syndrome myélodysplasique, à séquencer au moins un exon de DNMT3A compris dans l'échantillon, et à identifier des mutations, s'il y en a, dans le gène DNMT3A. La présence d'une ou plusieurs mutations dans DNMT3A peut indiquer que le sujet présente un risque élevé d'évolution défavorable.
PCT/US2011/059843 2010-11-08 2011-11-08 Méthodes de détermination du risque d'évolutions défavorables dans la leucémie myéloïde aiguë WO2012078288A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45656010P 2010-11-08 2010-11-08
US61/456,560 2010-11-08

Publications (2)

Publication Number Publication Date
WO2012078288A2 true WO2012078288A2 (fr) 2012-06-14
WO2012078288A3 WO2012078288A3 (fr) 2012-08-02

Family

ID=46207643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/059843 WO2012078288A2 (fr) 2010-11-08 2011-11-08 Méthodes de détermination du risque d'évolutions défavorables dans la leucémie myéloïde aiguë

Country Status (1)

Country Link
WO (1) WO2012078288A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017066566A1 (fr) * 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc Polythérapie pour le traitement de malignités
EP2997159B1 (fr) * 2013-05-13 2019-07-24 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Procédé de détermination de la prédisposition d'un individu humain à contracter une maladie myeloïde hematopoïetique maligne
US10449184B2 (en) 2014-03-14 2019-10-22 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
CN110564827A (zh) * 2019-09-19 2019-12-13 合肥艾迪康医学检验实验室有限公司 检测dnmt3a基因突变的引物、试剂盒和方法
US10640534B2 (en) 2012-01-19 2020-05-05 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
US10689414B2 (en) 2013-07-25 2020-06-23 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039805B1 (ru) * 2015-11-13 2022-03-15 Аджиос Фармасьютикалз, Инк. Комбинированная терапия для лечения злокачественных опухолей

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234997A1 (en) * 1998-06-25 2004-11-25 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
US20070198198A1 (en) * 2003-04-29 2007-08-23 Wyeth Methods and apparatuses for diagnosing AML and MDS
US20090317801A1 (en) * 2005-08-02 2009-12-24 Sequenom, Inc. Methods and compositions for disease prognosis based on nucleic acid methylation
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234997A1 (en) * 1998-06-25 2004-11-25 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
US20100159464A1 (en) * 2001-11-05 2010-06-24 Oncomedx, Inc. Method for Detection of DNA Methyltransferase RNA in Plasma and Serum
US20070198198A1 (en) * 2003-04-29 2007-08-23 Wyeth Methods and apparatuses for diagnosing AML and MDS
US20090317801A1 (en) * 2005-08-02 2009-12-24 Sequenom, Inc. Methods and compositions for disease prognosis based on nucleic acid methylation

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BULLINGER ET AL.: 'Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia.' N ENGL J MED. vol. 350, no. 16, 2004, pages 1605 - 1616 *
CHEN ET AL.: 'A Novel Dnmt3a Isoform Produced from an Alternative Promoter Localizes to Euchromatin and Its Expression Correlates with Active de Novo Methylation.' J BIOL CHEM. vol. 277, no. 41, 2002, pages 38746 - 38754 *
FRIED ET AL.: 'Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy- related and secondary acute myeloid leukemia.' HAEMATOLOGICA. vol. 97, no. 2, 2012, pages 246 - 250 *
LEY ET AL.: 'DNA sequencing of a cytogenetically normal acute myeloid leukemia genome.' NATURE. vol. 456, no. 7218, 2008, pages 66 - 72 *
LEY ET AL.: 'DNMT3A Mutations in Acute Myeloid Leukemia.' N ENGL J MED. vol. 363, no. 25, 16 December 2010, pages 2424 - 2433 *
LIN ET AL.: 'Recurrent DNMT3A R882 Mutations in Chinese Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.' PLOS ONE. vol. 6, no. 10, 2011, page E26906 *
RIBEIRO ET AL.: 'Mutant DNMT3A: a new marker of poor prognosis in acute myeloid leukemia.' BLOOD., [Online] 05 April 2012, Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/pubmed/22490330> [retrieved on 2012-05-07] *
ROBERTSON ET AL.: 'The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors' NUCLEIC ACIDS RES. vol. 27, no. 11, 1999, pages 2291 - 2298 *
SILVERMAN: 'The Role of Methyltransferase Inhibitors in the Management of the Myelodysplastic Syndromes.' CANCER CONTROL. vol. 11, no. 6, 2004, pages 11 - 15 *
YAMASHITA ET AL.: 'Array-based genomic resequencing of human leukemia.' ONCOGENE. vol. 29, no. 25, June 2010, pages 3723 - 3731 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11667673B2 (en) 2012-01-19 2023-06-06 Servier Pharmaceuticals Llc Therapeutically active compounds and their methods of use
US10640534B2 (en) 2012-01-19 2020-05-05 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US10717764B2 (en) 2012-01-19 2020-07-21 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP2997159B1 (fr) * 2013-05-13 2019-07-24 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Procédé de détermination de la prédisposition d'un individu humain à contracter une maladie myeloïde hematopoïetique maligne
US10689414B2 (en) 2013-07-25 2020-06-23 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US11021515B2 (en) 2013-07-25 2021-06-01 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US11504361B2 (en) 2014-03-14 2022-11-22 Servier Pharmaceuticals Llc Pharmaceutical compositions of therapeutically active compounds
US10449184B2 (en) 2014-03-14 2019-10-22 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US10799490B2 (en) 2014-03-14 2020-10-13 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
WO2017066566A1 (fr) * 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc Polythérapie pour le traitement de malignités
EA039805B1 (ru) * 2015-11-13 2022-03-15 Аджиос Фармасьютикалз, Инк. Комбинированная терапия для лечения злокачественных опухолей
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN110564827A (zh) * 2019-09-19 2019-12-13 合肥艾迪康医学检验实验室有限公司 检测dnmt3a基因突变的引物、试剂盒和方法

Also Published As

Publication number Publication date
WO2012078288A3 (fr) 2012-08-02

Similar Documents

Publication Publication Date Title
WO2012078288A2 (fr) Méthodes de détermination du risque d&#39;évolutions défavorables dans la leucémie myéloïde aiguë
Shen et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia
Pinto et al. Genomic landscape of paediatric adrenocortical tumours
Agraz-Doblas et al. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis
Dolnik et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing
Park et al. Characteristics of DNMT3A mutations in acute myeloid leukemia
Manojlovic et al. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases
Gale et al. Simpson's paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia
Dal Bo et al. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia
Maciejewski et al. Whole genome scanning as a cytogenetic tool in hematologic malignancies
Brecqueville et al. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase
Nigro Biology of childhood acute lymphoblastic leukemia
Yuferov et al. Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs
Hájková et al. Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation
Schranz et al. Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
Talseth-Palmer et al. Genetic variation and its role in malignancy
Gondek et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes
Barresi et al. Broad copy neutral‐loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype‐acute myeloid leukemia genomes
CN111575373B (zh) 基于多重pcr的靶向高通量测序的急性淋巴细胞白血病基因突变检测试剂盒及方法
KR20180108820A (ko) 암 후생유전적 프로파일링
Bim et al. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma
Caprini et al. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome
Shahrabi et al. Genetics and epigenetics of myelodysplastic syndromes and response to drug therapy: new insights
Edwards et al. Reassessment of weak parent-of-origin expression bias shows it rarely exists outside of known imprinted regions
El Wafi et al. Novel intronic RHD variants identified in serologically D‐negative blood donors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11846822

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11846822

Country of ref document: EP

Kind code of ref document: A2